Eli Lilly to Seek FDA Approval for New Migraine Drug -- Market Talk
August 04 2017 - 9:20AM
Dow Jones News
8:50 ET - Eli Lilly (LLY) says positive results from a Phase 3
study of its acute migraine treatment, lasmiditan, allows it to
submit a new drug application to the Food and Drug Administration
in 2H18. The second Phase 3 trial to end with positive results
included three different doses of the oral drug, each dose meeting
the key secondary endpoint and showing migraine improvement over a
two-hour period compared to the placebo, LLY says. LLY announced it
would acquire the drug's maker, CoLucid Pharmaceuticals, in
January, after it had succeeded in lasmiditan's first of two Phase
3 trials. LLY is up 1% premarket. (justina.vasquez@wsj.com)
(END) Dow Jones Newswires
August 04, 2017 09:05 ET (13:05 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
